Rehabilitation of functional muscle and motor capacity in neurodegenerative disease: Multiple Sclerosis research

Rehabilitation of functional muscle and motor capacity in neurodegenerative disease: a single centre placebo-controlled Multiple Sclerosis research trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN60122826

Enrollment

Registered

2009-10-01

Start date

2005-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

Patients will be subjected to different rehabilitation modes during a period of 24 weeks and according to a specific treatment protocol: 1. Control 2. Strength training 3. Strength training and electr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. MS patients (Expanded Standard Disbility Status Scale [EDSS] 0.5 - 3) that have functional muscle and motor functional disabilities 2. Males and females aged 20 - 65 years 3. 24-week availability

Exclusion criteria

Exclusion criteria: 1. Any pathology that is a contra-indication for rehabilitation training 2. Wheelchair dependency 3. No present physiotherapy (preferably)

Design outcomes

Primary

Measure	Time frame
Measured at baseline, mid- (after 10 weeks intervention) and post-treatment (after 20 weeks of intervention): 1. Maximal isometric muscle strength of knee-extensors and flexors 2. Isotonic and isokinetic dynamic muscle strength using an isokinetic dynamometer 3. Functional performances 4. Blood samples 5. Motor control (surface electromyography [sEMG], in-phase and anti-phase motor coordination test equipment) 6. Quality of life (specific questionnaire) assessment	—

Measure

Time frame

Measured at baseline, mid- (after 10 weeks intervention) and post-treatment (after 20 weeks of intervention): 1. Maximal isometric muscle strength of knee-extensors and flexors 2. Isotonic and isokinetic dynamic muscle strength using an isokinetic dynamometer 3. Functional performances 4. Blood samples 5. Motor control (surface electromyography [sEMG], in-phase and anti-phase motor coordination test equipment) 6. Quality of life (specific questionnaire) assessment

—

Secondary

Measure	Time frame
1. Visual Analogue Scale (VAS) measured before and after each training session 2. Borg Scale measured after each training session	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026